Last updated: August 11, 2026
LOZOL is the former U.S. brand for indapamide, a thiazide-like diuretic used primarily to treat hypertension and, at higher doses, edema associated with congestive heart failure. Its U.S. commercial value has largely migrated from the brand to generic indapamide. The product has no meaningful remaining market exclusivity, no biosimilar exposure, and limited standalone financial disclosure.
The commercial trajectory is defined by four factors: long-expired intellectual property, low-cost generic substitution, mature hypertension treatment guidelines, and competition from thiazide and thiazide-like alternatives such as hydrochlorothiazide and chlorthalidone.
What is LOZOL and how is indapamide used?
LOZOL contains indapamide, a sulfonamide-derived diuretic with antihypertensive activity. U.S. tablet strengths historically included 1.25 mg and 2.5 mg.
| Attribute |
LOZOL / indapamide |
| Active ingredient |
Indapamide |
| Drug class |
Thiazide-like diuretic |
| Primary use |
Hypertension |
| Secondary use |
Edema associated with congestive heart failure |
| U.S. dosage forms |
Immediate-release tablets, historically 1.25 mg and 2.5 mg |
| FDA pathway |
Original NDA approval |
| Current brand status |
Discontinued or commercially inactive in the U.S. |
| Generic status |
Available from multiple manufacturers |
| Biosimilar relevance |
None |
| Prescription status |
Prescription-only drug |
Indapamide reduces sodium and chloride reabsorption in the distal renal tubule. At antihypertensive doses, its blood-pressure effect is not fully explained by diuresis and includes reductions in peripheral vascular resistance.
The drug has been used as monotherapy and in combination with other antihypertensive agents. Generic indapamide remains relevant in markets where low-cost oral diuretics are used in long-term hypertension management.
What is the FDA regulatory status of LOZOL?
The FDA approved LOZOL in the early 1980s. FDA records identify indapamide products through the original new drug application and subsequent abbreviated new drug applications.
The current commercial status should be distinguished from regulatory withdrawal:
- A product may be listed as discontinued because the sponsor stopped marketing it.
- Discontinuation does not automatically mean the FDA withdrew approval for safety or efficacy reasons.
- Generic indapamide products can remain approved even after the branded product exits the market.
- The FDA’s Orange Book and Drugs@FDA databases are the controlling sources for application-level status.[1][2]
LOZOL’s commercial decline reflects market maturity rather than a known regulatory safety event. Generic indapamide tablets have continued to appear in FDA product and labeling databases.
What is the Orange Book status of LOZOL?
The original LOZOL product is associated with an older NDA record. The Orange Book distinguishes active marketed products from discontinued products and identifies patent and exclusivity information when applicable.
For a mature product such as LOZOL:
- Original brand exclusivity has expired.
- Any early formulation or product patents are no longer a practical barrier.
- Current generic approvals are generally based on the active ingredient and bioequivalence pathway.
- No commercially significant Orange Book patent protection is expected to block generic entry.
A current diligence review should rely on the FDA’s live Orange Book entry because application status, sponsor information, and product listings can change over time.[1]
When did LOZOL lose exclusivity?
LOZOL lost meaningful U.S. exclusivity decades ago. The original approval dates to the early 1980s, while modern generic competition entered after the relevant drug, formulation, and regulatory exclusivity periods expired.
| Exclusivity category |
LOZOL position |
| New chemical entity exclusivity |
Expired |
| Original brand market exclusivity |
Expired |
| Basic composition protection |
Expired or commercially irrelevant |
| Formulation protection |
Expired or commercially irrelevant |
| Method-of-use protection |
No known active barrier to generic hypertension use |
| Pediatric exclusivity |
Not commercially relevant |
| Orphan exclusivity |
Not applicable |
| Biosimilar exclusivity |
Not applicable |
Indapamide is a small-molecule drug, so the relevant competitive pathway is ANDA approval rather than biosimilar interchangeability.
What patents protect LOZOL?
No active, commercially material U.S. patent estate is expected to protect LOZOL or generic indapamide.
The original product’s patent position would have centered on:
- The indapamide active ingredient.
- Pharmaceutical compositions containing indapamide.
- Immediate-release oral tablets.
- Therapeutic use in hypertension and edema.
Those rights are historical rather than current commercial barriers. Public FDA records do not indicate a present Orange Book patent listing that would support a delayed generic-entry strategy for LOZOL.
What formulations are protected by LOZOL patents?
LOZOL was marketed as an immediate-release tablet. Any historical formulation claims would have covered the tablet composition, dosage strength, excipients, manufacturing process, or oral administration of indapamide.
The commercial consequences of those claims have ended. Generic manufacturers can compete with standard immediate-release indapamide tablets without facing a meaningful remaining LOZOL formulation monopoly.
Modified-release or combination products could create separate intellectual-property positions, but those products should not be treated as LOZOL protections unless they are specifically linked to an approved product and listed patent.
Which companies challenged LOZOL through Paragraph IV filings?
No current, material Paragraph IV litigation campaign is associated with LOZOL.
Paragraph IV certifications are relevant when a generic applicant challenges an unexpired Orange Book patent. LOZOL’s age and generic availability make a current Paragraph IV dispute unlikely to affect market access.
The practical generic-entry sequence was completed years ago:
- The brand product established the reference-drug record.
- Generic applicants filed ANDAs after the relevant protection expired.
- Generic manufacturers achieved approval through bioequivalence.
- Pharmacy substitution and payer formulary controls shifted demand away from LOZOL.
No publicly important settlement agreement is known to govern present U.S. access to generic indapamide.
How strong is the LOZOL patent estate?
The patent estate is commercially weak because its blocking life has ended.
| Patent-strength factor |
Assessment |
| Remaining U.S. term |
None of material commercial value |
| Generic entry barrier |
Low |
| Formulation differentiation |
Low for immediate-release tablets |
| Method-of-use protection |
Low |
| Manufacturing complexity |
Low to moderate |
| Substitution risk |
High |
| Litigation leverage |
Minimal |
| Licensing value |
Minimal |
Indapamide is a small-molecule oral solid with no complex biologic manufacturing process. Manufacturing requires standard pharmaceutical synthesis, formulation, compression, testing, and regulatory controls. These steps create quality and compliance obligations but do not create a durable proprietary barrier comparable to an injectable biologic, complex inhaled product, or specialized delivery system.
How does LOZOL compare with hydrochlorothiazide and chlorthalidone?
LOZOL competes in a mature diuretic market dominated by generic products. The main clinical and commercial comparators are hydrochlorothiazide and chlorthalidone.
| Product |
Class |
Market position |
Commercial risk to indapamide |
| Indapamide |
Thiazide-like diuretic |
Mature generic |
Competes on cost and physician familiarity |
| Hydrochlorothiazide |
Thiazide diuretic |
Broadest historical use |
Strong substitution pressure |
| Chlorthalidone |
Thiazide-like diuretic |
Guideline-supported, longer acting |
Strong clinical alternative |
| Combination antihypertensives |
Multiple classes |
Growing convenience segment |
Reduces standalone diuretic demand |
Hydrochlorothiazide has extensive historical use and broad availability in fixed-dose combinations. Chlorthalidone has gained attention because of its longer duration of action and use in hypertension guidelines. Indapamide remains clinically relevant, but its standalone brand economics are weak because physicians and payers can select among several low-cost alternatives.
The main competitive issue is not patent differentiation. It is prescribing preference, tolerability, formulary status, supply reliability, and availability in fixed-dose combinations.
What is the financial trajectory for LOZOL?
LOZOL does not have a separately disclosed public revenue stream in the financial reporting of major pharmaceutical companies. The brand’s financial trajectory is therefore best characterized qualitatively:
| Period |
Commercial and financial profile |
| 1980s |
Brand launch and protected-product economics |
| 1990s |
Generic-entry pressure and declining brand share |
| 2000s |
Mature generic market; reduced standalone brand value |
| 2010s |
Commercial discontinuation or low-volume brand activity |
| 2020s |
Generic indapamide market with limited brand contribution |
Revenue likely followed the standard lifecycle for an older oral antihypertensive:
- Initial revenue from branded prescriptions.
- Margin compression after generic entry.
- Volume migration to low-priced generic manufacturers.
- Declining reimbursement for the branded product.
- Eventual discontinuation, limited distribution, or conversion to an inactive brand listing.
The absence of separately reported LOZOL sales is itself commercially important. A branded product with material revenue would generally appear in segment reporting, product disclosures, or transaction materials. Indapamide is more likely to contribute to generic portfolios as a low-revenue, low-margin product than to generate meaningful brand cash flow.
What is the revenue exposure from LOZOL?
Revenue exposure is low for the original brand and diffuse for generic manufacturers.
A company holding a generic indapamide authorization may generate recurring sales from:
- Retail prescriptions.
- Institutional purchasing.
- Government reimbursement.
- Combination or adjacent antihypertensive portfolios.
The product’s low unit price limits absolute revenue. Demand can remain stable because hypertension is chronic, but stable prescription volume does not translate into high profitability. Generic pricing, wholesaler discounts, reimbursement pressure, and manufacturing competition determine margin.
LOZOL is therefore more relevant as a mature portfolio product than as a growth asset.
What generic entry risks exist for LOZOL?
Generic entry risk has already materialized. The remaining commercial risks affect generic suppliers rather than the former brand.
Price erosion
Multiple approved suppliers can reduce average selling prices. A manufacturer with a single-source or limited-source position could maintain better pricing temporarily, but standard indapamide tablets are vulnerable to new entrants.
Substitution by competing drugs
Prescribers can switch patients to hydrochlorothiazide, chlorthalidone, ACE inhibitor combinations, angiotensin receptor blockers, calcium-channel blockers, or fixed-dose products.
Supply-chain exposure
Small generic markets can experience intermittent shortages if one or two manufacturers exit. However, shortages can create temporary volume opportunities rather than durable pricing power.
Reimbursement compression
Medicare, Medicaid, commercial payers, and pharmacy benefit managers generally treat generic indapamide as a low-cost formulary product. Reimbursement pressure limits the value of incremental promotional spending.
What manufacturing and intellectual-property barriers affect indapamide?
Indapamide manufacturing has modest technical barriers but low proprietary defensibility.
Potential operational barriers include:
- Active pharmaceutical ingredient qualification.
- Control of impurities and degradation products.
- Content uniformity at low tablet strengths.
- Dissolution and stability testing.
- FDA current good manufacturing practice compliance.
- Reliable supply of active ingredient and excipients.
These requirements can delay a new supplier, but they do not create a durable patent moat. The product is an immediate-release tablet rather than a complex delivery system. Manufacturing know-how may support short-term cost advantages, but trade secrets are unlikely to prevent a capable generic manufacturer from entering.
What licensing deals involve LOZOL or indapamide?
No major current licensing transaction is publicly associated with LOZOL that would materially alter its U.S. market outlook.
Any historical rights transfers involving the brand, its original sponsor, or later commercial partners would have limited present value because the core exclusivity period has expired. Generic indapamide may be supplied under ordinary commercial agreements, contract manufacturing arrangements, or portfolio acquisitions, but these are different from strategic licensing transactions that create durable market control.
What patent litigation affects LOZOL?
No active, high-value U.S. patent litigation is known to materially affect LOZOL’s current market access.
The litigation profile is consistent with an old generic small molecule:
- No expected active brand-versus-generic patent dispute.
- No significant biosimilar litigation.
- No current settlement controlling generic entry.
- Limited incentive for a new formulation case unless a genuinely differentiated product is developed.
- Greater exposure to ordinary product-liability, manufacturing, labeling, or supply disputes than to patent litigation.
What is the likely generic launch scenario for LOZOL?
A new generic entrant would face a low legal barrier but a difficult commercial environment.
| Launch factor |
Expected effect |
| Patent barrier |
Minimal |
| FDA approval route |
ANDA |
| Clinical trial burden |
Limited relative to new-drug development |
| Price competition |
High |
| Brand loyalty |
Low |
| Pharmacy substitution |
High |
| Revenue upside |
Limited |
| Launch attractiveness |
Moderate for portfolio fit, weak as a standalone growth product |
The strongest rationale for entry would be an existing manufacturing platform, a supply agreement, or a broader generic hypertension portfolio. A standalone launch would likely produce modest revenue unless the entrant secured a temporary supply advantage.
How does LOZOL compare with other mature generic cardiovascular drugs?
LOZOL has a weaker commercial profile than mature products with large fixed-dose combination markets or higher prescription volumes. Its value is closer to that of a niche generic antihypertensive than a strategically important cardiovascular franchise.
| Commercial criterion |
LOZOL / indapamide |
| Prescription durability |
Moderate |
| Brand pricing power |
None |
| Generic competition |
High |
| Combination-product leverage |
Moderate |
| Patent value |
Negligible |
| Regulatory complexity |
Low to moderate |
| Manufacturing complexity |
Low to moderate |
| M&A value |
Portfolio-dependent |
| Growth potential |
Low |
Geographic performance may differ. Indapamide has maintained stronger recognition in some non-U.S. markets, particularly where it is incorporated into hypertension treatment protocols or fixed-dose combinations. U.S. commercial conclusions should not automatically be applied to Europe, Asia, or emerging markets because approval status, local brands, reimbursement, and patent histories differ by jurisdiction.
Key Takeaways
- LOZOL is the former branded product for indapamide, a thiazide-like antihypertensive diuretic.
- U.S. brand exclusivity expired decades ago.
- Generic indapamide is the relevant current commercial market.
- No material active LOZOL patent estate or current Paragraph IV dispute is expected to restrict generic access.
- The product has no biosimilar exposure because indapamide is a small molecule.
- Standalone LOZOL revenue is not separately disclosed and is likely immaterial.
- Generic indapamide has recurring clinical demand but limited pricing power.
- Hydrochlorothiazide, chlorthalidone, and fixed-dose antihypertensive combinations are the main competitive pressures.
- Manufacturing barriers are manageable and do not create a durable proprietary advantage.
- The product is more valuable as part of a generic portfolio than as an independent commercial asset.
FAQs
Is LOZOL still available in the United States?
The branded LOZOL product is generally treated as discontinued or commercially inactive in the United States. Generic indapamide tablets remain the relevant source of supply.
Is indapamide protected by active patents?
No commercially material U.S. patent protection is expected to remain for the original LOZOL immediate-release product or its basic hypertension use.
Can a generic manufacturer launch indapamide without a Paragraph IV challenge?
Yes. If no relevant unexpired Orange Book patent blocks the product, an ANDA applicant can use a certification pathway other than Paragraph IV, subject to FDA approval requirements.
Does indapamide have a meaningful biosimilar risk?
No. Biosimilar regulation applies to biological products. Indapamide is a chemically synthesized small molecule and competes through the generic-drug pathway.
Is indapamide a commercially attractive acquisition target?
Usually not as a standalone asset. Its value may be positive for a company with existing cardiovascular manufacturing, distribution, or portfolio infrastructure, but low price and generic competition limit strategic upside.
References
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. (n.d.). National Drug Code Directory. https://www.accessdata.fda.gov/scripts/cder/ndc/
- U.S. National Library of Medicine. (n.d.). DailyMed: Current medication information. https://dailymed.nlm.nih.gov/dailymed/
- U.S. Food and Drug Administration. (1983). LOZOL indapamide prescribing information. Drugs@FDA database. https://www.accessdata.fda.gov/scripts/cder/daf/
- Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115. https://doi.org/10.1161/HYP.0000000000000065
